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Abstract
Although doxorubicin toxicity in cancer cells is multifactorial, the enzymatic bioactivation of the drug can significantly
contribute to its cytotoxicity. Previous research has identified most of the components that comprise the doxorubicin
bioactivation network; however, adaptation of the network to changes in doxorubicin treatment or to patient-specific
changes in network components is much less understood. To investigate the properties of the coupled reduction/oxidation
reactions of the doxorubicin bioactivation network, we analyzed metabolic differences between two patient-derived acute
lymphoblastic leukemia (ALL) cell lines exhibiting varied doxorubicin sensitivities. We developed computational models that
accurately predicted doxorubicin bioactivation in both ALL cell lines at high and low doxorubicin concentrations. Oxygen-
dependent redox cycling promoted superoxide accumulation while NADPH-dependent reductive conversion promoted
semiquinone doxorubicin. This fundamental switch in control is observed between doxorubicin sensitive and insensitive
ALL cells and between high and low doxorubicin concentrations. We demonstrate that pharmacological intervention
strategies can be employed to either enhance or impede doxorubicin cytotoxicity in ALL cells due to the switching that
occurs between oxygen-dependent superoxide generation and NADPH-dependent doxorubicin semiquinone formation.
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Introduction
Doxorubicin (Adriamycin, Dox) is an antibiotic anthracycline
that is used frequently in chemotherapy for a variety of solid
tumors and leukemias [1,2,3]. The efficacy of doxorubicin
treatment is limited by drug resistance mechanisms [4,5,6].
Although the underlying mechanism of doxorubicin resistance is
not fully understood, researchers have determined several factors
that influence cellular doxorubicin toxicity, most notably the
expression of membrane transporters P-glycoprotein/MDR1 (Pgp)
[3,7,8,9] and the generation of reactive oxygen species (ROS) and
free radicals via doxorubicin redox cycling [10]. Because the
modulation of Pgp activity in vivo [8,9] and the use of antioxidants
[11,12] have failed to demonstrate any long term disease-free
survival, alternative mechanisms have been proposed to describe
the antitumor effects of doxorubicin and thereby offer plausible
explanations for why some cancers are sensitive to doxorubicin
treatment while others are not.
To this end, the reductive conversion of doxorubicin has been
implicated as a major determinant of doxorubicin cytotoxicity and
has been proposed as an underlying factor controlling drug
resistance in cancer cells [3,4,5,13]. Reductive conversion of
doxorubicin is characterized by the one-electron reduction of the
quinone moiety of doxorubicin, via NADPH and cytochrome
P450 reductase (CPR), into a semiquinone radical [3,14,15]. Once
the semiquinone radical has been generated, it can exert direct
toxic effects or be oxidized back to the quinone form (i.e. redox
cycling) [16]. The combination of bioreductive conversion and
redox cycling occurs simultaneously in mammalian cells; this
overall process is termed bioactivation. It has been reported that
the ability of doxorubicin to undergo reductive conversion is
dependent on the availability of molecular oxygen and NADPH,
and the activities of several intracellular enzymes such as
superoxide dismutase (SOD), glutathione peroxidase, NADPH
oxidases (NOXs), and thioredoxin [1,2,3,4,5,6,15], components
whose intracellular concentrations and activities may vary from
one cancer type to the next, or from patient to patient. This
variation may help explain some of the contradictory evidence in
the literature that describes the proper intracellular environment
or intervention strategy for effectively controlling doxorubicin
toxicity in vivo [4,5,6,12,16,17,18]. For example, doxorubicin-
resistant MCF-7 breast cancer cells showed little change in SOD
activity compared to their doxorubicin-sensitive counterparts [5];
however, in another study doxorubicin-sensitive MCF cells were
rescued via the introduction of SOD [6]. Furthermore, despite the
central role of CPR in the bioactivation process, the importance of
this enzyme in modulating doxorubicin toxicity has been called
into question. While it is widely accepted that CPR is the primary
enzyme for catalyzing the reductive conversion of doxorubicin in
vivo [17,19], overexpression of CPR does not result in enhanced
doxorubicin cytotoxicity [16].
Because the overall network structure for cytosolic doxorubicin
bioactivation is believed to be conserved across different cell types
[4,20,21], the contradictory behavior described above is most
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components (both metabolites and proteins) between cells. In vitro
studies carried out by Kostrzewa-Nowak et al support this
hypothesis by showing that changes in NADPH concentration
and SOD activity had a direct impact on degree of doxorubicin
reductive conversion [3]. This dependence of the drug on
[NADPH] becomes very important in light of recent findings that
frequently-occurring somatic mutations in gliomas and leukemias
can result in a directional change from NADPH production to
NADPH consumption by isocitrate dehydrogenases (IDH1/2)
resulting in lower intracellular NADPH levels [22,23]. Addition-
ally, several lines of evidence in the literature have pointed to the
involvement of NOX activity in doxorubicin treatment, providing
added relevance to the intracellular levels of NADPH in
doxorubicin bioactivation [24]. Thus, the redox context-depen-
dence of doxorubicin metabolism becomes central to accounting
for patient variability to anthracycline regimens. Contradictory
observations regarding the redox-mediated reactions involved in
conferring doxorubicin potency highlight the need for a more in-
depth quantitative examination of how the behavior of the
doxorubicin bioactivation network is influenced by the initial levels
of its system components and its component interactions. The
objective of the present study, therefore, was to (a) determine the
intracellular factors that control doxorubicin bioactivation for
different doxorubicin treatment conditions, (b) develop a mecha-
nistic model of doxorubicin bioactivation in leukemia cells that
could be interrogated to predict resistance to doxorubicin
treatment prior to clinical administration of the drug, and (c) test,
through simulation, the possible intervention strategies that could
be employed to modulate doxorubicin cytotoxic activity in
leukemia. We exploited previously-published in vitro characteriza-
tion of the biochemical steps involved in doxorubicin bioactivation
to develop models that were specific for patient-derived ALL cell
lines. Our model findings, confirmed in two cell lines, indicate that
doxorubicin metabolism can shift between NADPH-dependent
reductive conversion, which drives doxorubicin toxicity in
leukemia cells, and NADPH-dependent superoxide generation,
which drives doxorubicin-dependent signaling. Nonintuitively,
NADPH-dependent ROS production is associated with protection
against doxorubicin-induced cell death. Furthermore, redox
control over doxorubicin bioactivation is regulated not just by
the enzymatic reactions that take place within the cell, but also by
the concentration of doxorubicin to which the cell is exposed.
Results
A computational model describes in vitro doxorubicin
bioactivation
To investigate the mechanisms that control doxorubicin
bioactivation, we developed a kinetic mathematical model of the
doxorubicin bioactivation network in a cell free system (Fig. 1).
From here on, we shall use the term in vitro to refer to acellular
systems and the term in vivo to refer to cellular systems. Our in vitro
model was used to reproduce previously published in vitro data
generated by Kostrzewa-Nowak et al on the effect of NADPH
concentration on doxorubicin bioactivation [3]. In the model, we
allowed for the reaction of NADPH with molecular oxygen, but
assumed it to be non-enzymatic since NADPH oxidase was not
present in the cell free reaction mixtures. The inclusion of the
NADPH/O2 reaction in the bioactivation network model was
particularly important because it provided a mechanistic pathway
by which increased NADPH concentration could lead to
enhanced doxorubicin reductive conversion. Reductive conversion
of doxorubicin is characterized by conservative NADPH depletion
and quinone doxorubicin transformation, while redox cycling of
doxorubicin is characterized by rapid NADPH depletion and
sustained quinone doxorubicin. The completed in vitro model was
capable not only of describing the switch in behavior between
reductive conversion and redox cycling of doxorubicin (Fig. 1A, B)
based upon the high and low NADPH concentrations, but was
also capable of replicating a new experimental condition. Upon
inclusion of SOD activity in the bioactivation network, without
refitting the parameters, the model demonstrated SOD-induced
redox cycling of doxorubicin at high NADPH concentration
(Fig. 1C) [3].
Doxorubicin sensitivity and bioactivation network
components differ in EU1 and EU3 ALL cells
The validated in vitro model of doxorubicin bioactivation
emphasizes the importance of the reaction between NADPH
and molecular oxygen in the accurate representation of doxoru-
bicin bioactivation. Moreover, the model illustrates how the
driving force of [NADPH] and levels of SOD can control the
switching between reductive conversion and redox cycling. We
therefore hypothesized that the intrinsic differences in protein
expression and redox state between leukemia cells could similarly
give rise to shifts in control between these two processes,
conferring differences in doxorubicin cytotoxicity. In support of
this hypothesis, others have observed that treatment of the HL60
human leukemia cell line with bioactivated doxorubicin led to
increased cytotoxic activity compared to treatment with nonacti-
vated, or redox cycled, doxorubicin [3]. These findings suggest
that reductive conversion of doxorubicin may be an important
determinant of doxorubicin toxicity in leukemia cells. To further
investigate this possibility by computational modeling, we
characterized the doxorubicin sensitivity of two ALL cell lines,
EU1 (EU1-Res) and EU3 (EU3-Sens), that were previously
reported to have over a 10-fold difference in IC50 to doxorubicin
[25]. The EU1-Res line displayed limited toxicity to doxorubicin
treatment, retaining greater than 100% viability even after
Author Summary
In the United States, acute lymphoblastic leukemia (ALL) is
the most common form of cancer among children.
Although the survival rate of childhood leukemia is
relatively high, those who do not respond to chemother-
apy have very low prognostic outcome. Recent reports
point to the critical role of metabolism in determining cell
sensitivity to doxorubicin, a conventional drug used in
leukemia treatment. Most of the molecular components
involved in doxorubicin metabolism have been identified;
however, how these components operate as a system and
how adaptation of the doxorubicin metabolic network to
patient-specific changes in protein components is much
less understood. We have therefore chosen to investigate
via computational modeling the variations in the distribu-
tion of proteins that metabolize doxorubicin can control a
cell’s ability to respond to doxorubicin treatment. This
systems-level approach provides a framework for under-
standing how patient-specific variability leads to patient-
sensitivity to doxorubicin treatment at different doses.
With this knowledge, we were able to correctly predict
complex behavior induced by pharmacological interven-
tion strategies for manipulation of doxorubicin metabo-
lism. When our interventions are used in combination with
doxorubicin, cell viability was promoted or potentiated
based on dominant control mechanisms within the
metabolic network.
Network Control of Doxorubicin Bioactivation
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Sens cell line showed decreased viability after exposure to
doxorubicin concentrations as low as 40 nM for the same
treatment duration (Fig. 2B).
We characterized the relative mRNA expression levels and
activities of the enzymes involved in cytosolic doxorubicin
bioactivation (Fig. 2C–D) for these two cell lines. The cellular
bioactivation network differs from the in vitro one by the inclusion
of additional pertinent biochemical reactions (Fig. 2A). Glucose-6-
phosphate dehydrogenase (G6PD) enzymatic activity is the
primary source for regenerating reduced NADPH in normal
metabolism [26] and NADPH oxidases rely on oxygen and
NADPH to produce superoxide. It has been previously reported
that NOX activity is involved in doxorubicin-induced cell death,
implicating NOXs in the cellular doxorubicin bioactivation
network [24]. NOX4 is the NADPH oxidase isoform that controls
constitutive superoxide production, whereas other isoforms are
considered to be activated during signal transduction [27]. The
EU1-Res cells contain significantly higher NOX4 mRNA levels
and CPR activity, compared to the EU3-Sens cells (p,0.05)
(Fig. 2D). EU1-Res cells have significantly lower G6PD mRNA
levels (Fig. 2C) and activity (Fig. 2D) (p,0.05). There was no
significant difference in the levels of SOD1 mRNA, or SOD1
activity, between the EU1-Res and EU3-Sens cells (Fig. 2C, 2D).
There was a direct correlation between mRNA expression and
enzyme activity for the enzymes under consideration.
Figure 1. Three proposed mechanisms for in vitro doxorubicin bioactivation. (A–C) Experimental data [3] and model fitted results for
different doxorubicin bioactivation pathways accompanied by a schematic representation of the hypothesized network underlying each pathway.
Large fonts denote experimental conditions in which the [NADPH] was increased from 100 mM to 500 mM.
doi:10.1371/journal.pcbi.1002151.g001
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PLoS Computational Biology | www.ploscompbiol.org 3 September 2011 | Volume 7 | Issue 9 | e1002151Figure 2. Doxorubicin sensitivity and bioactivation network components differ in EU1 and EU3 ALL cells. (A) Scheme describing in vivo
doxorubicin bioactivation. (B) Cell viability for EU1-Res and EU3-Sens cells, determined by WST1 assay, after 3 hr doxorubicin treatment at varied
concentrations. (C–D) Relative mRNA levels and enzyme activities of enzymes involved in doxorubicin bioactivation in ALL cells. (*p,0.05).
doi:10.1371/journal.pcbi.1002151.g002
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for ALL cells
To examine whether differences in mRNA expression levels and
activities of doxorubicin bioactivation enzymes would result in
differences in doxorubicin bioactivation between the EU1-Res and
EU3-Sens cell lines, we measured intracellular doxorubicin
accumulation in the ALL cells for 1 hr during a 10 mM
doxorubicin treatment. The EU1-Res cells had significantly higher
quinone doxorubicin accumulation compared to the EU3-Sens
cells, starting at 40 min of treatment and lasting for the remaining
treatment duration (P,0.05) (Fig. 3A). These results were not a
function of differential doxorubicin efflux/influx as both the EU1-
Res and EU3-Sens cells displayed negligible PgP efflux activity,
and the rate of doxorubicin consumption from the cell medium
was not significantly different between the cells (Fig. S1, Fig. S2).
Because NADPH depletion and superoxide production can be
indicators for the extent of doxorubicin reductive conversion that
has taken place within a cell [3], we monitored doxorubicin-
induced NADPH depletion and superoxide generation in both cell
lines. NADPH depletion due to 10 mM doxorubicin treatment was
significantly lower in the EU3-Sens cells compared to the EU1-Res
cells, starting as early as 10 min into the treatment regimen and
continuing this trend for the duration of the treatment (p,0.05)
(Fig. 3B). Doxorubicin-induced superoxide generation, measured
by HydroCy5, a molecular probe with specificity for
NOH and
O2
N2 [28], was significantly higher in the EU3-Sens cells than in
the EU1-Res cells starting 30 min into the treatment regimen and
lasting for the remainder of the treatment duration (p,0.05)
(Fig. 3C).
Two in vivo models were generated for the EU1-Res and EU3-
Sens cells based upon the network structure depicted in Fig. 2A
(See Materials and Methods). The differences in quinone
doxorubicin accumulation (Fig. 3A) and superoxide generation
(Fig. 3C) between the EU1-Res and EU3-Sens cells were
accurately captured by the kinetic model simulations. Although
kinetic model simulations of doxorubicin-induced NADPH
depletion were able to reproduce the depletion trends seen in
both the EU1-Res and the EU3-Sens cells, the magnitude of
NADPH-depletion in both cell lines was slightly underestimated
compared to experimental results (Fig. 3B). Both experimental
measurements and model simulations of doxorubicin-induced
intracellular doxorubicin accumulation, NADPH depletion, and
superoxide generation suggest that the extent of doxorubicin
reductive conversion in EU1-Res and EU3-Sens cells differ
significantly. The EU1-Res cells exhibited higher quinone
doxorubicin accumulation, more NADPH depletion, and lower
superoxide generation, which are all consistent with decreased
reductive conversion/increased redox cycling, as evidenced by the
data generated by our validated in vitro model. Conversely, the
EU3-Sens cells exhibited lower quinone doxorubicin accumula-
tion, lower doxorubicin-induced NADPH depletion, and higher
doxorubicin-induced superoxide generation, which are consistent
with the in vitro conditions that characterize increased doxorubicin
reductive conversion (Fig. 1B, Fig. 3A–C). These results suggest an
intrinsic mechanistic switch between redox cycling and reductive
conversion that takes place in the EU1-Res and EU3-Sens cells,
one that is a function of cell-specific levels of intracellular
doxorubicin bioactivation components.
Concentration-dependence of doxorubicin bioactivation
in ALL cells
Because the apparent switch between redox cycling and
reductive conversion appeared to be driven by different catalytic
rates within the drug metabolism network, we asked whether the
concentration of doxorubicin would affect the behavior of the
coupled redox reactions. To examine whether differences in the
doxorubicin concentration applied to the cells could alter the
doxorubicin bioactivation profile of the EU1-Res and EU3-Sens
cells, we again analyzed intracellular doxorubicin accumulation,
doxorubicin-induced NADPH depletion and doxorubicin-induced
superoxide generation in the ALL cells for 1 hr during a 100 nM
doxorubicin treatment regimen. The 100 nM doxorubicin con-
centration represents a 100-fold change in doxorubicin concen-
tration compared to the 10 mM doxorubicin treatment regimen
previously administered to the cells. Our experimental results show
that the overall shape of the quinone doxorubicin accumulation
curve for both ALL cells at the 100 nM doxorubicin treatment
level was significantly different that that seen for the 10 mM level.
At the 10 mM doxorubicin treatment level, there was a steady
increase in the accumulation of quinone doxorubicin in both cell
lines as a function of time, although the rate of increase was higher
in the EU1-Res cells than the EU3-Sens cells (Fig. 3A).
Conversely, at the 100 nM doxorubicin treatment level, there
was a rapid increase in quinone doxorubicin accumulation at
10 min, but this increase was followed by a sharp decrease in
intracellular quinone doxorubicin which then appeared to
equilibrate to a steady state level that was maintained for the
rest of the treatment duration (Fig. 3D). Additionally, for the
100 nM doxorubicin treatment regimen, the intracellular quinone
doxorubicin levels in the EU1-Res cells were significantly lower
than those seen in the EU3-Sens cells (p,0.05) (Fig. 3D),
representing a complete switch in behavior compared to that seen
at the 10 mM doxorubicin treatment level (Fig. 3A). Without
additional parameter fitting, the kinetic simulation of the low
doxorubicin treatment condition was able to capture the decreased
amounts of quinone doxorubicin observed in the EU1-Res cells,
compared to the EU3-Sens cells, as well as the general shape of the
intracellular quinone doxorubicin accumulation curve (Fig. 3D),
providing further validation of the quality of the cell-line specific
models for explaining the complex responses we observed
experimentally.
The doxorubicin-induced NADPH depletion in the EU1-Res
cells was not significantly different from that seen in the EU3-Sens
cells (Fig. 3E). While model simulations accurately predicted
similar NADPH depletion trends between EU1-Res and EU3-
Sens cells, the underestimation of NADPH depletion in the model
simulations was still apparent at the 100 nM doxorubicin
concentration condition (Fig. 3E). Differences in doxorubicin-
induced superoxide generation between the EU1-Res and EU3-
Sens cells were negligible (Fig. 3F) and kinetic model simulations of
doxorubicin-induced superoxide generation accurately captured
this behavior. The lack of sustained accumulation of quinone
doxorubicin in both the EU1-Res and EU3-Sens cells, paired with
the experimentally determined NADPH depletion and superoxide
generation profiles at the 100 nM doxorubicin treatment condi-
tion, suggest that both the EU1 and EU3 cells undergo a shift in
the control of their doxorubicin metabolism profiles as a result of
changes in the doxorubicin treatment condition applied.
Model-generated hypotheses of altered NADPH and
quinone doxorubicin dynamics are confirmed by
pharmacological intervention in drug-sensitive cells
Concentration-dependent differences in doxorubicin bioactiva-
tion exist between the EU1-Res and the EU3-Sens cells (Fig. 3).
Based on these differences, we hypothesized that successful
intervention strategies for altering the behavior of the doxorubicin
bioactivation network within ALL cells would also be doxorubicin
Network Control of Doxorubicin Bioactivation
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cell line, we conducted a series of pharmacological intervention
strategies, for both the 10 mM and the 100 nM doxorubicin
concentration condition, that were aimed at decreasing the amount
of doxorubicin reductive conversion that occurs within the EU3-
Sens cells. We opted to adjust NADPH regeneration (k8/k9) using
the pharmacological G6PD inhibitor, dehydroepiandrosterone
(DHEA), because NADPH is involved in the CPR- and oxygen-
dependent enzymatic reactions that play a role in reductive
conversion and redox cycling of doxorubicin (Fig. 2). Furthermore,
simulations of G6PD inhibition on doxorubicin bioactivation in
EU3-Sens cells for the 10 mM doxorubicin concentration condition
predicted an appreciably increased accumulation of quinone
doxorubicin and an increased depletion of NADPH over one hour
(Fig. 4A, B). These processes are indicative of increased redox
cycling of doxorubicin, at the expense of doxorubicin reductive
conversion, and are similar to the dynamics that occur in the
doxorubicin-resistant EU1-Res cells (Fig. 3A). Our model predic-
tions were confirmed through pharmacological modification of
G6PD activity by the G6PD inhibitor, DHEA, for the 10 mM
doxorubicin concentration condition (Fig. 4A, B).
Next, we utilized our kinetic model to simulate the effect of
G6PD inhibition on doxorubicin reductive conversion in EU3-
Sens cells for the 100 nM doxorubicin concentration condition.
Our model predicted that inhibition of G6PD activity in the EU3-
Sens cells would have no effect on the accumulation of quinone
doxorubicin or the depletion of NADPH over one hour (Fig. 4A,
B). Our in silico model predictions of the behavior of the
doxorubicin bioactivation network after pharmacological inter-
vention at the 100 nM doxorubicin concentration condition were
also confirmed (Fig. 4A, B).
NADPH supply potentially alters viability of doxorubicin-
treated ALL cells by controlling semiquinone doxorubicin
formation and superoxide generation in a doxorubicin
concentration-dependent manner
To further explore the concentration-dependent effects of
DHEA treatment on doxorubicin bioactivation, we used the
cellular network models of doxorubicin bioactivation to quantify
the fluxes of semiquinone doxorubicin formation and superoxide
generation in both the EU1-Res and EU3-Sens cells with and
without DHEA treatment. Our analyses suggest that inhibition of
NADPH production by G6PD at 10 mM doxorubicin concentra-
tion leads to a decrease in the formation of semiquinone
doxorubicin in both the EU1-Res and EU3-Sens cells (Fig. 5A),
Figure 4. Effects of pharmacological intervention on doxorubicin reductive conversion in EU3-Sens cells. (A) Model-predicted and
experimentally determined quinone doxorubicin accumulation in EU3-Sens cells, with and without DHEA intervention, at the 10 mM and 100 nM
doxorubicin concentration conditions. (B) Model-predicted and experimentally determined NADPH depletion in EU3-Sens cells, with and without
DHEA intervention, at the 10 mM and 100 nM doxorubicin concentration conditions. (DHEA=10 mM, 24 hrs; *p,0.05).
doi:10.1371/journal.pcbi.1002151.g004
Figure 3. Concentration-dependence of doxorubicin bioactivation in ALL cells. Experimentally-determined and model-predicted quinone
doxorubicin accumulation (A), doxorubicin-induced NADPH depletion (B), and doxorubicin-induced superoxide generation (C) in ALL cells treated
with 10 mM Dox for 1 hr (*p,0.05). Experimentally-determined and model-predicted quinone doxorubicin accumulation (D), doxorubicin-induced
NADPH depletion (E), and doxorubicin-induced superoxide generation (F) in ALL cells treated with 100 nM Dox for 1 hr (*p,0.05).
doi:10.1371/journal.pcbi.1002151.g003
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in either cell line at the 100 nM doxorubicin condition. Because
DHEA will indirectly impact the NADPH-dependent NOX4 by
substrate limitations, we also analyzed superoxide fluxes. The
models demonstrate that DHEA decreases O2
N2 production in all
conditions and cell lines except the EU3-Sens cells at the 10 mM
doxorubicin treatment condition (Fig. 5B).
To relate our model findings to experimentally determined
changes in cell viability, we analyzed both EU1-Res and EU3-Sens
cell survival for the different doxorubicin treatment conditions
using a WST1 cell viability assay. Corresponding to our model
simulated predictions of quinone doxorubicin accumulation
(Fig. 4A), NADPH depletion (Fig. 4B) and semiquinone doxoru-
bicin flux (Fig. 5A), we observed that DHEA was able to rescue
EU3-Sens cells from doxorubicin-induced cytotoxicity at the
10 mM doxorubicin concentration condition. Conversely, we
found that DHEA treatment at the 10 mM doxorubicin concen-
tration condition significantly decreased cell viability of the EU1-
Res cells (p,0.05) (Fig. 5C). At the low doxorubicin concentration
condition, DHEA treatment still enhanced doxorubicin toxicity in
the EU1-Res cells (Fig. 5C), to a similar degree. However, in the
EU3-Sens cells, DHEA treatment at the 100 nM doxorubicin
concentration condition enhanced doxorubicin toxicity (Fig. 5C),
rather than prevent it.
Discussion
Although the anthracycline drug doxorubicin is used clinically
for the treatment of leukemias and solid tumors [1,2,3], the
efficacy of doxorubicin treatment is limited by the development of
drug resistance [4,5,6]. Evidence points to the reductive
conversion of doxorubicin as an important ‘first step’ in the
regulation of doxorubicin toxicity [2,3,4,5,13]. While the doxoru-
bicin bioactivation network has been studied extensively, with the
overall network structure for cytosolic doxorubicin bioactivation
having been deciphered and believed to be conserved across
Figure 5. NADPH supply alters doxorubicin sensitivity in ALL cells in a concentration- and cell-dependent manner. (A) in silico model
predictions of NADPH-dependent semiquinone doxorubicin flux in ALL cells, with and without DHEA intervention, at the 10 mM and 100 nM
doxorubicin concentration conditions. (B) in silico model predictions of NADPH-dependent superoxide flux in ALL cells, with and without DHEA
intervention, at the 10 mM and 100 nM doxorubicin concentration conditions. (C) Experimentally determined (WST1 assay) cell viability for ALL cells
after 3 hr doxorubicin treatment, at the 10 mM and 100 nM doxorubicin concentration conditions. (DHEA=10 mM, 24 hrs; *p,0.05).
doi:10.1371/journal.pcbi.1002151.g005
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network to changes in the levels of system components or changes
in doxorubicin concentration is much less well understood. Here
we show that the doxorubicin bioactivation network is a dynamic
system that is sensitive to network component levels and
doxorubicin concentrations. Moreover, we illustrate that the
intracellular doxorubicin bioactivation network is capable of
executing multiple modes of doxorubicin metabolism; the network
contains toxicity-generating and ROS-generating reactions that
control doxorubicin metabolism via reductive conversion or redox
cycling. We illustrate how these reactions can be modulated by
pharmacological intervention strategies to either enhance or
hinder doxorubicin toxicity in a concentration-dependent manner.
Validation of an in vitro doxorubicin bioactivation model reveals
that the reaction of molecular oxygen with NADPH is a necessary
and significant component of the overall doxorubicin bioactivation
network. By analyzing the in vitro doxorubicin bioactivation
network under the distinctively different conditions described by
Kostrzewa-Nowak et al [3], we observed three distinct pathways
by which doxorubicin is metabolically altered: CPR-independent
redox cycling, CPR-dependent redox cycling, and reductive
conversion.
The CPR-independent redox cycling of quinone doxorubicin is
the first method by which doxorubicin can be metabolically
altered (Fig. 1A). This form of redox cycling of doxorubicin
dominates when NADPH is limited. The in vitro system has no way
of recycling oxidized NADPH once it has reacted with oxidized
CPR; when reduced NADPH has been fully consumed, the
reduction of quinone doxorubicin by CPR can no longer take
place. At this point, the only reactions that can occur are the
oxygen-dependent redox cycling reactions of doxorubicin (k3/k5),
which result in a zero net transformation of the quinone
doxorubicin molecule and the generation of superoxide.
The second doxorubicin metabolic pathway to consider is the
CPR-dependent redox cycling of doxorubicin. CPR-dependent
redox cycling of doxorubicin is very similar to CPR-independent
redox cycling of doxorubicin in that there is a zero net
transformation of quinone doxorubicin into its semiquinone form
(Fig. 1C). However, whereas CPR-independent redox cycling
takes place at low [NADPH] conditions, CPR-dependent redox
cycling takes place when high concentrations of NADPH and
molecular oxygen are present simultaneously. When these two
conditions are met, the rapid reduction of quinone doxorubicin via
CPR occurs, maintained by the high levels of NADPH in the
system; the rapid reoxidation of semiquinone doxorubicin by
molecular oxygen also occurs, maintained by the SOD-dependent
regeneration of molecular oxygen. The analogous in vivo scenario
was observed in both the EU1-Res and EU3-Sens cells at the low
doxorubicin concentration condition (Fig. 3D–F). The NADPH
fraction for both cell lines was maintained at a nearly constant
level due to the non-enzymatic reactions defined by k3/k5.
Superoxide is produced as a byproduct to a significant degree
for a 100-fold lower doxorubicin treatment due to CPR-dependent
redox cycling.
The third and final doxorubicin metabolic pathway to consider
is the reductive conversion of doxorubicin. When the flux of
doxorubicin semiquinone production exceeds the flux of doxoru-
bicin semiquinone consumption, there is a net transformation of
quinone doxorubicin into its semiquinone form (Fig. 1B).
Doxorubicin reductive conversion dominates at the in vitro high
[NADPH] condition because there is enough NADPH to support
the CPR-mediated reduction of quinone doxorubicin, forcing
doxorubicin semiquinone production to overwhelm doxorubicin
semiquinone consumption by molecular oxygen. Furthermore, the
increased NADPH level diminishes oxygen-dependent semiqui-
none doxorubicin consumption (k5) because NADPH effectively
competes with semiquinone doxorubicin for molecular oxygen.
We observed the dominance of reductive conversion, in vivo, with
the EU3-Sens cells during the 10 mM doxorubicin treatment
regimen (Fig. 3A). This behavior occurred because as the EU3-
Sens cells have an increased capacity to reduce oxidized NADPH,
as evidenced by their higher G6PD mRNA and activity levels,
they can drive a stronger flux through CPR than their EU1-Res
counterparts (Fig. 3A).
After investigating the NADPH-dependent doxorubicin semi-
quinone and superoxide fluxes that occur during doxorubicin
treatment of EU1-Res and EU3-Sens cells, at both the high and
the low doxorubicin concentration conditions, and comparing
these model generated fluxes to our experimental viability studies
(Fig. 5C), we conclude that the doxorubicin bioactivation network
is comprised of a toxicity-generating module and a ROS-
generating module that likely is implicated in additional signaling
(Fig. 6). Our models suggest that at different doxorubicin
concentrations, certain components become limiting in either
Figure 6. Proposed model of doxorubicin metabolism in ALL cells that emphasizes the toxicity-generating and signal-generating
modules comprising the network. The toxicity-generating module is NADPH-limited at the high Dox condition, allowing DHEA administration to
decrease NADPH-dependent semiquinone doxorubicin formation. The signal-generating module is NADPH-limited at the low Dox condition, allowing
DHEA administration to decrease NADPH-dependent superoxide formation.
doi:10.1371/journal.pcbi.1002151.g006
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and these limiting components effectively determine the extent of
doxorubicin toxicity that a cell will experience.
Prior in vitro biochemical studies have established a minimal
concentration of NADPH required to promote the reductive
conversion of doxorubicin in vitro [3]. We propose that there is a
cell-specific set-point of intracellular NADPH availability, as
determined by G6PD activity, above which the modulation of
NADPH concentration will have little effect on the ROS-
generating module of doxorubicin bioactivation within a particular
cell. At the high doxorubicin concentration condition, DHEA
promoted decreased superoxide flux in the EU1-Res cells, whereas
it had little effect on the EU3-Sens cells (Fig. 5B). This is most
likely due to the fact that the basal level of NADPH in the EU1-
Res cell is already below the threshold level at which the ROS-
generating module of doxorubicin bioactivation can be affected by
changes in G6PD activity. We have shown experimentally that the
basal level of NADPH in the EU1-Res cell is significantly lower
than that of the EU3-Sens cell (Fig. S3) making it more susceptible
to the effects of DHEA at the high doxorubicin concentration
condition, as evidenced by the strong effect of DHEA on cell
viability (Fig. 5C). The inhibition of G6PD activity by DHEA at
the high doxorubicin concentration condition was able to rescue
EU3-Sens cells from doxorubicin induced toxicity because it
selectively hindered CPR-dependent doxorubicin reductive con-
version (Fig. 5A–C) without affecting the ROS-generating module
of doxorubicin bioactivation; the threshold of NADPH below
which the ROS-generating module becomes compromised had
not yet been reached in the EU3-Sens cells.
Inhibition of G6PD at the low doxorubicin concentration
condition did not rescue any of the ALL cells from doxorubicin
toxicity, but rather promoted doxorubicin-induced cell death.
Because doxorubicin has been shown to activate NOXs in vivo
[24], NOX activity can be thought of as being dependent on
[NADPH], [O2], and [Dox]. Therefore, at the low doxorubicin
concentration, compared to high, more NADPH is needed to
maintain the same level of NOX activity; this effectively lowers the
NADPH threshold of the signal generating module. The NOX
reaction becomes more sensitive to [NADPH] at the low
doxorubicin condition and DHEA can effectively decrease
NOX-induced superoxide flux for both cell lines (Fig. 5C).
Inspection of the trends between the model fluxes (Fig. 5A–B)
and the resultant cytotoxicity (Fig. 5C) suggests that perturbation
of the bioactivation network by DHEA affects the CPR-driven
reductive conversion component (red module, Fig. 6) at 10 mM
doxorubicin and the ROS-producing redox cycling component
(green module, Fig. 6) at 100 nM doxorubicin.
It has already been shown in the literature that doxorubicin
reductive conversion increases doxorubicin toxicity in cancer cells
[3,17] and our findings corroborate this understanding. When we
related our experimental viability studies with our model-
simulated flux analyses for the EU1-Res and EU3-Sens cells, a
distinct pattern emerged: conditions that hindered the toxicity-
generating module of doxorubicin bioactivation decreased doxo-
rubicin-sensitivity, while conditions that hindered the ROS-
generating module of doxorubicin bioactivation increased doxo-
rubicin-sensitivity. Moreover, cell-specific levels of NADPH, and
to some extent the cell-specific activities of G6PD, determined the
ultimate effect of G6PD pharmaceutical perturbation on cell
viability at each doxorubicin condition investigated. Therefore,
during doxorubicin treatment, one can assume that both the
toxicity- and the ROS-generating modules of doxorubicin
bioactivation are functioning within a given cancer cell. It is the
relative dominance of either the toxicity- or the ROS-generating
modules of doxorubicin bioactivation that will ultimately deter-
mine cell sensitivity to doxorubicin treatment. A systemic
approach to understanding how variability in enzyme activity
and concentration control both the toxicity- and the ROS-
generating modules of the doxorubicin bioactivation network may
provide more efficacious strategies for cancer chemotherapy [29].
We have shown that by limiting the influence of the ROS-
generating module of doxorubicin bioactivation, we can effectively
promote doxorubicin-induced toxicity in the EU1-Res cell line
(Fig. 5), whereas previously it was resistant to doxorubicin
treatment (Fig. 2B). Based on these results, it is possible that
doxorubicin-induced NOX-dependent ROS generation in the
ALL lines serves as a second messenger for downstream signaling
pathways that contribute to cell viability. The idea of ROS
modulating cell viability is not unprecedented as several
intracellular signaling pathways are known to be redox sensitive,
the most notable being the NF-kB pathway [30]. The transcrip-
tion factor NF-kB itself is a redox-sensitive protein [31,32,33]
known to potentiate cell survival during chemotherapy treatment
[34,35,36,37]. Thus, the resulting effect of ROS generation on cell
viability most likely involves other downstream signaling pathways.
We have shown that concentration-dependence of doxorubicin
bioactivation exists in leukemia cells, with oxygen-dependent,
ROS-generating reactions having greater influence over doxoru-
bicin toxicity at low doxorubicin concentrations. If this concen-
tration-dependence is exhibited by a variety of other transformed
or non-transformed cells, it could help explain the conflicting
evidence in the literature regarding the importance of different
enzymatic systems in conferring doxorubicin sensitivity
[4,5,6,12,16,17,18]. Work conducted by Asmis et al seems to
support the universality of our findings. They observed in
macrophages that at low doxorubicin concentrations (0–2 mM)
there is a concentration-dependent decrease in the ratio of reduced
to oxidized glutathione (GSH/GSSG), a marker or increased
oxidative stress; however, when doxorubicin concentrations were
increased from 2 mMt o5 mM, the GSH/GSSG ratio was
recovered [38]. This finding appears to be in line with our
conceptual understanding that at low doxorubicin concentrations,
the ROS-generating module of doxorubicin bioactivation is more
significant than it is at high doxorubicin concentrations, where it
gives way to the toxicity-generating module. The ROS-generating
module, however, may also be capable of promoting cell injury in
some cell lines. In the same study, Asmis et al report that
doxorubicin-induced ROS modified glutathione-dependent thiol
oxidation in macrophage cells to promote increased cell injury,
implicating both glutathione reductase and glutaredoxin enzymes
in the management of doxorubicin-induced cell injury [38]. This
result suggests that cell-specific antioxidant capacity may ulti-
mately determine whether doxorubicin-induced ROS promotes
cell viability, by modifying signaling pathways, or whether it
promotes cell death, by inducing cellular damage via a thiol
oxidation-based mechanism.
The two cell-line specific models of doxorubicin bioactivation
have demonstrated predictive power and have recapitulated the
dynamics of the doxorubicin bioactivation network for multiple
conditions. The model behavior, however, falls short in explaining
the delayed onset of O2
N2 or the initial drop in NADPH upon
doxorubicin treatment. One reason for this model limitation could
be our description of the NADPH-dependent NOX4 enzymatic
reaction that utilizes NADPH and molecular oxygen to produce
superoxide. The reaction of NADPH with molecular oxygen, as a
result of NOX4 activity, was modeled as a function of the
concentrations of NADPH, molecular oxygen, and intracellular
quinone doxorubicin because it has been shown previously in the
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activity in other cell types [24]. Although we have incorporated the
doxorubicin-dependence of NOX activity in our ALL models, the
lack of knowledge on the exact mechanism by which this
interaction occurs introduces some uncertainty into the mathe-
matical formulation we utilized to describe this reaction in our
model system. However, it should be noted that our modeling
analyses do support the idea that without doxorubicin-dependent
NOX activation our description of doxorubicin bioactivation was
limited in its ability to thoroughly describe the effect of
doxorubicin treatment on NADPH utilization and superoxide
generation by the cell.
An additional limitation of our in vivo models comes from the
fact that our models are incomplete in scope. There are multiple
mechanisms for anthracycline bioactivation in mammalian cells:
the mitochondria-dependent bioactivation of doxorubicin by
mitochondrial complex I and NADH [39,40], and the mitochon-
dria-independent mechanisms of doxorubicin bioactivation by
CPR and NADPH [19]. Furthermore, some studies have placed
the cytotoxic action of doxorubicin in the nuclear compartment of
mammalian cells [41]. As it currently stands, our model only
considers cytosolic doxorubicin bioactivation, and is therefore
inherently limited. Additionally, our in vivo doxorubicin bioactiva-
tion network includes species that are involved in a variety of other
intracellular reactions which are independent of doxorubicin
bioactivation, such as NADPH. NADPH is a metabolite that is
used ubiquitously in cells for a variety of redox dependent
reactions [42]. Moreover, NADPH-dependent thiol oxidation-
based mechanisms may actually contribute to doxorubicin-
induced cell injury in some cells [38], thereby providing a link
between intracellular thiol-disulfide status and doxorubicin-
induced toxicity; a link that was unaccounted for by our model
system because of the qualitative nature of the findings.
The ability of the current in vivo models to accurately explain the
experimental data and predict new conditions does not immedi-
ately preclude alternate mechanisms that may be at work. It is
entirely possible that mechanisms beyond the scope of these
models contribute to the cell-line differences in doxorubicin
sensitivity that are exhibited between the EU1-Res and EU3-Sens
cells. We have already provided evidence that altered doxorubicin
transport may not be a primary cause of the differential
doxorubicin-sensitivity that exists between the EU1-Res and the
EU3-Sens cell lines (Fig. S1, Fig. S2). However, non-transport
related mechanisms such as altered doxorubicin detoxification,
altered replication behavior, or altered ROS metabolism could
play a significant role in the doxorubicin toxicity profiles exhibited
by these cells, and the importance of these alternate mechanisms
may emerge upon characterization of additional cell lines.
Doxorubicin detoxification is thought to be mediated by both
one- and two-electron pathways of quinone reduction that depend
on the activities of cellular reductases and glutathione S-
transferases [19,43,44,45]. Cell-to-cell variation in these enzymes
could account for differences in cell sensitivity to doxorubicin
treatment. Furthermore, since most mammalian xenobiotic
detoxification sytems rely on the addition of a glutathione moeity,
via glutathione S transferases [43], variations in the glutathione
redox potential of these cells could also contribute to the variations
in doxorubicin-sensitivity that are exhibited between the two cells.
Moreover, if ROS metabolism is a key factor that determines the
sensitivity of cancer cells to doxorubicin treatment, as was
suggested by the proposed signaling actions of the ROS-generating
module, then differences in glutathione redox potential and
differences in other NADPH-consuming mechanisms could
effectively promote or hinder doxorubicin toxicity in these cells.
Because additional mechanisms of doxorubicin toxicity may
exist, the systematic analysis of these alternate mechanisms are
necessary to assess their relative importance in vivo. To this end, the
current descriptions of doxorubicin bioactivation offered by this
study can serve as preliminary models to which additional modules
can be easily added. For instance, if one wanted to assess the effect
of varied ROS buffering capacity or ROS production on
doxorubicin sensitivity across different cell lines, one could merge
a comprehensive model of ROS buffering in mammalian cells [42]
to the current models. In doing so, experimentally-measured cell-
specific values of model components can be inserted into these
aggregated models to determine how variations in cell components
could affect such aspects as the formation of toxic doxorubicin
metabolites, or the ROS-mediated posttranslational modifications
that can alter intracellular signaling pathways leading to altered
cell growth and proliferation. In this way, future modeling efforts
can be utilized to test the contributions of redox and non-redox
based mechanisms to the overall levels of doxorubicin-sensitivity
experienced by a particular cell.
In summary, examining the cytosolic doxorubicin bioactivation
pathway from a systems biology perspective has provided insight
into the redox-dependent mechanisms that may be responsible for
conferring doxorubicin sensitivity in cancer cells. Kinetic modeling
of the electron transfer mechanisms demonstrates that the
doxorubicin bioactivation pathway is dual natured and dynamic,
exhibiting sensitivity to initial levels of system components, as
defined by cell specific enzyme levels, as well as doxorubicin
concentration conditions. We have shown through mathematical
modeling and experimental analysis, that the toxicity-generating
module of doxorubicin bioactivation overwhelms the ROS-
generating module in the EU3-Sens cell line, whereas the ROS-
generating module of doxorubicin bioactivation overwhelms the
toxicity-generating module in the EU1-Res cell line. This
discrepancy in doxorubicin metabolism between the EU1-Res
and EU3-Sens cells determines the effectiveness of pharmacolog-
ical intervention strategies that are aimed at modifying doxoru-
bicin induced toxicity. The model elucidates an important role for
NAPDH supply, as modulated by G6PD activity, in controlling
concentration-dependent doxorubicin cytotoxicity in tumor cells.
We demonstrate an approach to enhance doxorubicin cytotoxicity
via the pharmacological modification of G6PD activity in both the
EU1-Res and EU3-Sens leukemia cell lines. We have also
demonstrated, however, that this same intervention strategy used
in concert with a high dose of doxorubicin or within a cell
containing protein expression levels that promote reductive
conversion can actually promote cell viability rather than impede
it. The dynamic nature of the doxorubicin bioactivation network,
and its ability to metabolize doxorubicin via distinctively different
modes, allows for the controlled manipulation of the system to
either promote cell viability, as would be desired when protecting
non-transformed cells from unwanted doxorubicin toxicity, or to
promote doxorubicin-induced transformed-cell death. Finally,
because the quinone structure of doxorubicin is conserved across
the anthracycline drug family, future studies may elucidate similar
control mechanisms in the metabolism of other anthracyclines by
cancer cells.
Materials and Methods
Computational modeling
Ordinary differential equation [46] models of in vitro and in vivo
doxorubicin bioactivation were developed based on the scheme
proposed by Kostrzewa-Nowak et al [3]. Here, the term in vitro
refers to experiments conducted in solution, while the term in vivo
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model, which describes doxorubicin activation in the presence of
NADPH and CPR, contains 6 kinetic parameters and 9 ODEs (see
Tables 1 and 2) that describe the changes in concentration of 9
compounds that structure the doxorubicin bioactivation network
(doxorubicin, metabolites, redox enzymes and reactive oxygen
species). The in vivo model, which describes doxorubicin activation
in the presence of NADPH, CPR, G6PD, SOD1, and NOX4 is an
adaptation of the in vitro model and contains 10 kinetic parameters
and 10 ODEs (see Tables 3 and 4). The in vitro and in vivo
mathematical models developed in this study use mass action
kinetics to describe the enzymatic and non-enzymatic reactions
that result in the redox cycling and reductive conversion of
doxorubicin. The computational models were designed and
numerically integrated using MATLAB R2008a (The Mathworks,
Inc., Natick, MA, USA).
Major assumptions of the computational model
To accurately describe the effect of NADPH concentration on
the mode of doxorubicin bioactivation that takes place, we allowed
the NADPH molecule to react slowly with molecular oxygen in the
in vitro model. Although this reaction is known to take place in vivo
through the enzymatic actions of NADPH oxidases [24], due to
the high concentration of NADPH contained in the reaction
mixture, we assumed the non-enzymatic reaction of NADPH with
molecular oxygen could be possible, and as a result, included this
reaction at a low rate in the network model of in vitro doxorubicin
bioactivation. For the in vivo kinetic model of doxorubicin bio-
activation, we assumed the reaction was catalyzed by NADPH
oxidases in a mass action-driven reaction that was dependent on
doxorubicin concentration, as it has been shown that doxorubicin
treatment can activate NOXs in a doxorubicin concentration-
dependent manner [24]. For both the in vitro and in vivo models, we
assumed doxorubicin degradation was negligible within the time
period investigated in the study.
The concentration of intracellular molecular oxygen used in the
in vivo model was derived from literature reported values of oxygen
consumption in the HL-60 human leukemia cell line [47]. The
rate of oxygen consumption in the HL-60 cell line was reported to
be significantly lower than the rate of oxygen consumption in the
non-transformed murine macrophage cell line J774A [47,48]. We
used the intracellular oxygen concentration measured for the
J774A cell line, in conjunction with the reported oxygen
consumption rates for the transformed HL-60 and non-trans-
formed J774A cell lines, to estimate the intracellular concentration
of oxygen in the EU1-Res and EU3-Sens lymphoblastic leukemia
cell lines [47,48]. While this may be an inexact estimate of the
actual concentration of oxygen in the cell lines being modeled, it
does underscore the limited oxygen environment under which
cancer cells proliferate [49].
Doxorubicin transport across the cell membrane, as modeled in
the in vivo models of doxorubicin bioactivation, was described by a
concentration gradient multiplied by the permeability constant of
doxorubicin. It has been shown previously in the literature that
doxorubicin uptake by cells is characterized by a linear diffusive
component as well as a saturable, carrier-mediated component [50].
Asimplifiedversionofthedoxorubicinuptakeequation,aspresented
by El-kareh et al [50], was utilized in the description of doxorubicin
bioactivation for the EU1-Res and EU3-Sens cell lines at the high
doxorubicin concentration condition. It was assumed that at low
doxorubicin concentrations, the saturable, carrier-mediated compo-
nent of doxorubicin uptake was negligible; therefore for the low
doxorubicin concentration condition we utilized a simple diffusion-
based equation to describe doxorubicin permeation across the cell
membrane [42]. Additionally, it was assumed that the permeability
constant for doxorubicin at the low doxorubicin concentration
was106higherthanthepermeability constant for doxorubicin at the
high doxorubicin concentration based on findings by Ghosn et al
that illustrated an inverse relationship between solute concentration
and solute permeability coefficient [51].
Parameter fitting
Unknown parameters in the in vitro doxorubicin activation model
were fitted to in vitro experimental data generated by Kostrzewa-
Nowak et al. [3]. The fitted parameter values for the in vitro model
were then used, where applicable, in the in vivo doxorubicin
bioactivation model and additional parameter fits were made using
experimental data generated from doxorubicin-treated ALL cells.
The parameter set of the in vitro model contains 6 kinetic
parameters and 9 initial conditions. Three of the 6 kinetic
parameters that make up the in vitro model were fitted to
experimentally determined data sets (Table 2). In the fitting
procedure, we used the experimental data provided by Kostrzewa-
Nowak and colleagues describing the in vitro redox cycling and
reductive conversion of doxorubicin at varied concentrations of
NADPH, doxorubicin, cytochrome P450 reductase (CPR), and
superoxide dismutase (SOD) [3]. Because the model is comprised
of a simple network with a relatively small number of parameters,
parameter fitting was conducted by minimizing the rudimentary
cost function, U:
U~
X 2
j~1
X 11
k~1
Y
(th)
j (tk){Y
(exp)
j (tk)
hi 2
, ð1Þ
Where Y
(exp)
j (tk) and Y
(th)
j (tk) represent the experimental and
theoretical (model predicted) data, respectively, of doxorubicin
and NADPH (j=1,2), at time points tk=0, 2, 4, … , 20 minutes
(k=1, 2, … , 11). As an initial approximation of the model
parameters to be fitted, we used parameter values estimated from
the literature for similar types of enzyme-catalyzed reactions
[52,53]. For fitting purposes, Y
(exp)
j (tk) and Y
(th)
j (tk) were
normalized to their maximal values. All the parameters used in
the in vitro model are shown in Table 2.
The catalysis of semiquinone doxorubicin was modeled by a two-
step process involving first the reduction of doxorubicin by CPR
Table 1. Initial concentration values for the species utilized in
the in vitro Dox model.
Species Abbreviation
Initial Condition
(M) Reference
Reduced CPR CPRred 1.0|10
26 [3]
Oxidized CPR CPRox 0 Assumption
Quinone Doxorubicin Doxq 1.0|10
24 [3]
(SQ) Doxorubicin Doxsq 0[ 3 ]
NADPH NADPH 1.0|10
24/
5.0|10
24
[3]
NADP
+ NADP
+ 0 Assumption
Molecular Oxygen O2 2.7|10
24 [56]
Superoxide O2
2 0 Assumption
Hydrogen Peroxide H2O2 0 Assumption
doi:10.1371/journal.pcbi.1002151.t001
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reaction rate of reduced CPR with quinone doxorubicin (Reaction
R1, Table 2) was fitted to the data in [3] for the redox cycling of
doxorubicin; the reaction rate for NADPH reacting with molecular
oxygen (Reaction R4, Table 2) was fitted to experimental data
showing the reductive conversion of doxorubicin [3]; the reaction
rate for superoxide anion reacting with quinone doxorubicin
(Reaction R5, Table 2) was fitted to experimental data showing the
SOD-induced redox cycling of doxorubicin [3]. The cost function,
U, was minimized independently for each fitted parameter because
the data used in the fitting procedure was generated from three
independent experiments with different sets of initial conditions [3].
The initial conditions for the in vitro model were taken directly from
the in vitro experiments describing redox cycling, reductive
conversion, and SOD-induced redox cycling of doxorubicin [3].
The in vivo kinetic models of doxorubicin bioactivation were
based upon the fitted in vitro model of doxorubicin bioactivation
that was adapted as indicated in Figure 2A. The parameter set of
the model contains 10 kinetic parameters, six of which were either
taken directly or estimated from the fitted in vitro model, and 10
initial conditions. Two of the 10 kinetic parameters that make up
the in vivo model had to be fitted to experimentally determined
data (Table 4). In the fitting procedure, we used the 10 mM [Dox]
NADPH depletion data for the EU1-Res cell line to fit k8, the
parameter that describes the rate of NADPH supply by the G6PD
enzyme, and we used 10 mM [Dox] extracellular doxorubicin
depletion data for the EU1-Res cell line to fit k7, the parameter
that describes the permeability coefficient of doxorubicin (Fig. S2).
These parameter fits were conducted for the EU1-Res model only.
To determine the fitted parameter value, we minimized the
following cost function, U:
U~
X 7
k~1
½Y(exp)(tk){Y(th)(tk) 
2,
[54] where Y(exp)(tk) and Y(th)(tk) represent the experimental
and theoretical (model predicted) data, respectively, of intracellular
NADPH or extracellular doxorubicin for the EU1-Res cell line, at
time points tk=0, 10, …, 60 minutes (k=1, …, 7). As an initial
approximation of the model parameter to be fitted, we used
parameter values estimated from the literature [42]. For the fitting
of parameter k8, Y(exp)(tk) and Y(th)(tk) were normalized to their
maximal values. Most of the parameters fitted to the EU1-Res
experimental data, were used unaltered in the EU3-Sens in vivo
model. However, to model experimentally determined enzymatic
differences between the doxorubicin-resistant EU1-Res cell line
and the doxorubicin-sensitive EU3-Sens cell line, we utilized the
experimentally determined fold change values between the EU1-
Res and EU3-Sens cell lines to estimate appropriate parameter
values for the EU3-Sens cell line based on the EU1-Res values
previously determined. This method was used to determine the
EU3-Res cell line rate constants for NOX4-dependent superoxide
generation (k4), SOD-dependent superoxide dismutation (k6), as
well as G6PD-dependent NADPH reduction (k8).
Because some degree of variation may exist in the values of
some of the parameters used in the model, due to limitations in
measurement accuracy or due to the inherent differences that exist
among in vivo cell populations, systematic sensitivity analysis was
conducted to determine the extent to which the model predicted
results would change as a function of parameter variation (Fig. S4).
Details of this sensitivity analysis are highlighted in Text S1.
Tests of pharmacological interventions were conducted in silico
using the fitted in vivo models of doxorubicin bioactivation and
assuming 20% inhibition of each target.
Materials, cell culture and treatment conditions
All reagents were from Sigma-Aldrich unless otherwise specified.
Two ALL cell lines representing major phenotypes of childhood
Table 2. Reaction expressions and parameter values for the in vitro Dox model.
Rxn No. Expression Parameter Reference
R1 k1 ([CPRred]) ([Doxq]) k1=1.2|10
4 M
21 s
21 Fitted
R2 k2 ([CPRox]) ([NADPH]) k2=k 1 [3]
R3 k3 ([O2]) ([Doxsq]) k3=3.0|10
8 M
21 s
21 [57]
R4 k4 ([NADPH]) ([O2]) k4=2.9|10
1 M
21 s
21 Fitted
R5 k5 ([O2
2]) ([Doxq]) k5=5.5|10
7 M
21 s
21 Fitted
R6 k6 ([O2
2]) ([O2
2]) k6=6.4|10
9 M
21 s
21 [52]
doi:10.1371/journal.pcbi.1002151.t002
Table 3. Initial concentration values for the species utilized in
the in vivo Dox models.
Species Abbreviation
Initial
Condition (M) Reference
Reduced CPR: (EU1-Res) CPRred 1.3|10
26 [58]
Reduced CPR: (EU3-Sens) CPRred 8.9|10
27 Measured
¥
Oxidized CPR CPRox 0 Assigned
Extracellular (Q)
Doxorubicin
Ex_Doxq 1.0|10
25/
1.0|10
27
Assigned
Intracellular (Q)
Doxorubicin
In_Doxq 0 Assigned
Intracellular (SQ)
Doxorubicin
In_Doxsq 0 Assigned
NADPH: (EU1-Res) NADPH 3.0|10
25 [59]
NADPH: (EU3-Sens) NADPH 5.4|10
25 Measured
¥
NADP: (EU1-Res) NADP NADP=0.01
|NADPH
[60]
NADP: (EU3-Sens) NADP NADP=0.01
|NADPH
[60]
Molecular Oxygen O2 1.5|10
29 [47,48]
Superoxide O2
2 1.5|10
211 Assigned
Hydrogen Peroxide H2O2 1.5|10
211 Assigned
¥Measured=Fold change between the resistant and sensitive cell lines (as
described in materials and methods) multiplied by the species concentration
value for the resistant cell line.
doi:10.1371/journal.pcbi.1002151.t003
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previously characterized [25,55]. ALL cell lines were cultured in
RPM1-1640 medium supplemented with 10% FBS and 100 U/ml
ofpenicillin/streptomycin andgrown ina humidified atmosphereof
5% CO2 at 37uC. For all experiments, unless otherwise stated, cells
were resuspended in fresh media (1|10
6 cells/ml) and treated with
various concentrations of doxorubicin (Enzo Life Sciences),
protected from light and incubated at 37uC. Phenol-red-free
medium was comprised of phenol-red-free RPMI-1640 medium
supplemented with 10% FBS and 100 U/ml of penicillin/
streptomycin. For treatments requiring DHEA, ALL cells were
incubated in ALL media with the DHEA solution (DHEA in 10%
DMSO/90% ALL media) at a final concentration of 10 mMa n d
incubated for 24 hrs prior to dox treatment.
Cell viability and apoptosis
ALL cells were treated with a range of doxorubicin concentra-
tions for various time periods. After treatment, cell viability was
assayed with the cell proliferation reagent WST1 (Roche Applied
Science) according to the manufacturer’s protocol, using a Synergy
4 hybrid microplate reader (Biotek, Winooski, VT, USA).
Doxorubicin accumulation
ALL cells plated in 96-well plate format (1|10
6 cells/ml) were
treated with doxorubicin (10 mM or 100 nM) and protected from
light at 37uC. Absorbance was read for 1 hr, every 10 min, using a
Synergy 4 hybrid microplate reader (Absorbance=480 nm). The
absorbance readings of wells containing media and doxorubicin
without any cells, and wells containing cells and media without
any doxorubicin, were used as controls.
NADPH measurement
ALL cells plated in 96-well plate format treated with
doxorubicin (10 mM or 100 nM) were protected from light at
37uC. Absorbance was read for 1 hr, every 10 min, using a
Synergy 4 hybrid microplate reader (Absorbance=340 nm). The
absorption readings of wells containing media and doxorubicin
without any cells, and wells containing cells and media without
any doxorubicin, were used as controls. In addition, the
absorbance readings of wells containing media and peroxide
without any cells, and wells containing media and peroxide with
cells, were used as positive controls for NADPH depletion.
Cellular fractionation and ER isolation
Doxorubicin-treated and untreated cells were pelleted by
centrifugation for 5 min at 300|g. Cytoplasmic fractions were
obtained by lysing in 2% NP-40 buffer containing 50 mM b-
glycerophosphate, 10 mM NaPP, 30 mM NaF, 50 mM Tris-
HCL, pH 7.5, 150 mM NaCl, 1 nM benzamidine, 2 nM EGTA,
100 mM sodium orthovanadate, 1 mM DTT, 10 mg/ml aprotinin,
10 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mg/ml microcystin-LR,
and 1 mM PMSF. Cells were lysed on ice for 1 hr, followed by
centrifugation for 10 min at 14.5|g. For CPR activity analysis,
endoplasmic reticulum (ER) isolation from doxorubicin-treated
and untreated cells was conducted using the ER isolation kit
(Sigma-Aldrich) according to the manufacturer’s protocol.
Enzyme activity measurements
Basal G6PD and CPR activities were determined in EU1-Res
and EU3-Sens cells using the Glucose-6-Phosphate Dehydrogenase
Assay Kit (BioVision, Mountain View, CA, USA), and the
Cytochrome c Reductase (NADPH) Assay Kit (Sigma), respectively,
according to the manufacturers’ protocols. SOD activity was
determined using the Superoxide Dismutase Activity Colorimetric
Assay Kit according to the manufacturer’s protocol (AbCam).
qRT PCR measurements
RNA was isolated from cells using the RNeasy isolation kit with
RNase-free DNase set according to the manufacturer’s protocol.
1 mg of RNA was used for reverse transcription. For detection of
mRNA levels, a custom RT2 Profiler PCR Array was used,
according to the manufacturer’s protocol. The following PCR
conditions were used: 10 min at 95uC; 40 cycles of 1 minute at
60uC and 15 seconds at 95uC; melt curve with ramp from 60uCt o
Table 4. Reaction expressions and parameter values for the in vivo Dox models.
Rxn No. Expression Parameter Reference
R1 k1 ([CPRred]) ([Doxq]) k1=1.2|10
4 M
21 s
21 in vitro model
R2 k2 ([CPRox]) ([NADPH]) k2=k 1 in vitro model
R3 k3 ([O2]) ([Doxsq]) k3=3.0|10
5 M
21 s
21 [10,13,57]
R4: (EU1-Res) k4 ([NADPH]) ([O2]) k4=4.2|10
4 M
21 s
21 [56]
R4: (EU3-Sens) k4 ([NADPH]) ([O2]) k4=9.7|10
3 M
21 s
21 Measured
¥
R5 k5 ([O2
2]) ([Doxq]) k5=5.5|10
7 M
21 s
21 in vitro model
R6 k6 ([O2
2]) ([O2
2]) k6=6.4|10
9 M
21 s
21 in vitro model
R7:1 0mMk 7 ([Ex_Doxq]) (A)
{ k7=1.1|10
26 cm s
21 Fitted
I
R7: 100 nM k7 ([Ex_Doxq]) (A)
{ k7=1.1|10
25 cm s
21 [51]
R8: (EU1-Res) k8 ([NADP])/( k9+[NADP]) k8=1.8|10
26 Ms
21
k9=5.7|10
25 M
Fitted
[61]
R8: (EU3-Sens) k8 ([NADP])/( k9+[NADP]) k8=3.3|10
26 Ms
21
k9=5.7|10
25 M
Measured
¥
[61]
{A=10
23 (L cm
23)|6.15|10
26 (cm
2)|1|10
9 (cells/L).
¥Measured=Fold change between the resistant and sensitive cell lines (as determined by basal SOD and G6PD activity) multiplied by the parameter value for the
resistant cell line.
IThe permeability constant for doxorubicin permeation is non-constant for the duration of doxorubicin treatment. See Materials and Methods/Text S1 for detailed
description.
doi:10.1371/journal.pcbi.1002151.t004
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One Plus system. Results were normalized to the expression of b-
actin. Relative expression levels were calculated using the DCT
method (2
2DCT). All arrays were performed with triplicate sets of
RNA isolation for each cell line for statistical analysis.
Intracellular ROS determination
For determination of doxorubicin-induced O2
N2 formation, cells
were plated at a density of 1|10
6 cells/ml and pre-incubated with
50 mM Hydro-Cy5 dye [28] resuspended in DMSO for 15 min.
After pre-incubation, 10 mM doxorubicin was added to respective
wells and kinetic fluorescence readings were taking with the
microplate reader every 10 min for 1 hr (Ex=635 nm, Em=
660 nm). Unstimulated cells, pre-incubated with and without
Hydro-Cy5 dye, and phenol red-free media, pre-incubated with
and without Hydro-Cy5 dye and doxorubicin, respectively, were
used as controls.
Statistical analysis
All values reported are the average of three or more
independent biological replicates +/2 standard error. Statistical
significance is based upon the criteria of p,0.05 for a Student’s
t-test (two-tailed, equal variance).
Supporting Information
Figure S1 PgP activity in the EU1 and EU3 cells are
equivalent and non-significant. Dye efflux characterization
for ALL and AML cell lines indicating that the doxorubicin-
resistant EU1 cells and the doxorubicin-sensitive EU3 cells are not
significantly different, regarding their PgP activities, from the PgP-
AML cell line. (*p,0.05).
(EPS)
Figure S2 Doxorubicin transport for EU1 and EU3 cells
are equivalent. Extracellular doxorubicin depletion for doxo-
rubicin-resistant EU1 and doxorubicin-sensitive EU3 cells.
([Dox]=10 mM for 1 hr; *p,0.05).
(EPS)
Figure S3 Basal NADPH levels are significantly differ-
ent between the EU1 and EU3 cells. Relative basal
intracellular [NADPH] in doxorubicin-resistant EU1 and doxo-
rubicin-sensitive EU3 cells determined by absorbance readings.
(340 nm; *p,0.05).
(EPS)
Figure S4 Sensitivity analysis of model parameters and
species concentrations. Selected parameters and species initial
conditions were systematically perturbed (610%) and the model-
predicted effects of these variations on quinone doxorubicin
accumulation, NADPH depletion, and superoxide production
were assessed. The initial values used for the sensitivity analysis, x,
were taken from the EU1-Res cell model at the 10 mM
doxorubicin concentration condition. These values were then
increased by 10% (+10%) or decreased by 10% (210%),
independently, and then model simulations were carried out: k
indicates the parameters for which the kinetic rate constants were
varied (G6PD, SOD1, and NOX4) and []indicates the
parameters for which the initial concentrations were varied
(NADPH, CPR, and O2). Model sensitivity analysis was conducted
for a 10 mM doxorubicin treatment regimen. Normalized
sensitivity coefficients (Si) (See Text S1 for details) were calculated
to quantitatively characterize the effect of each parameter
perturbation on quinone doxorubicin accumulation, NADPH
depletion, and superoxide production, respectively. The normal-
ized sensitivity coefficients are shown in Figure S4.
(EPS)
Text S1 Material and Methods for supplemental figures
S1–S4.
(DOC)
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